Provectus Pharmaceuticals (PVCT) Stock Statistics & Valuation Metrics

Provectus Pharmaceuticals has a market cap or net worth of $19.92M. The enterprise value is $22.83M.

Provectus Pharmaceuticals has 420,279,880 shares outstanding. The number of shares has decreased by -2.65% in one year.

Provectus Pharmaceuticals’s return on equity (ROE) is 0.79 and return on invested capital (ROIC) is 141.75%.

The current PE Ratio of Provectus Pharmaceuticals is ―. Provectus Pharmaceuticals’s PEG ratio is -0.20.

In the last 12 months, Provectus Pharmaceuticals had revenue of 617.14K and earned -4.73M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -8.42M and capital expenditures 0.00, giving a free cash flow of -8.42M billion.

Provectus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Provectus Pharmaceuticals upcoming earnings date is ―, ―.

Provectus Pharmaceuticals as a current ratio of 0.14, with Debt / Equity ratio of -57.86%

In the past 12 months, Provectus Pharmaceuticals has paid -9.32K in taxes.

Provectus Pharmaceuticals EV to EBITDA ratio is -11.78, with an EV/FCF ratio of -16.23.

Provectus Pharmaceuticals has $72.48K in cash and marketable securities with $3.57M in debt, giving a net cash position of -$3.50M billion.

Gross margin is -8.89%, with operating margin of -640.81%, and net profit margin of -766.92%.

The average price target for Provectus Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―